Novocell Obtains U.S. Patent For Drug Screening Human Embryonic Cell Derived-Endoderm Cells
Novocell, Inc., a stem cell engineering company, announced that it has received U.S. Patent No. 7,541,185 with method claims covering the use of endoderm cells derived from human embryonic stem cells (hESCs) for drug discovery. This is the second U.S. patent issued to Novocell related to human endoderm. U.S. Patent No.
[Read the full article here]Related News:
Novocell Obtains U.S. Patent for Drug Screening Human Embryonic Cell …
Novocell awarded seminal stem cell patent
Novocell gets patent for innovative stem cell therapy for diabetes